Document Detail

Fibrinolytic agents for peripheral arterial occlusion.
MedLine Citation:
PMID:  20238313     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Peripheral arterial thrombolysis is used in the management of peripheral arterial ischaemia. Streptokinase was originally used but safety concerns led to a search for other agents. Urokinase and recombinant tissue plasminogen activator (rt-PA) have increasingly become established as first line agents for peripheral arterial thrombolysis. Potential advantages of these agents include improved safety, greater efficacy and a more rapid response. Recently drugs such as pro-urokinase, recombinant staphylokinase and alfimperase have been introduced.
OBJECTIVES: To determine which fibrinolytic agents are most effective in peripheral arterial ischaemia.
SEARCH STRATEGY: The Cochrane Peripheral Vascular Diseases Group searched their Specialised Register (last searched October 2009) and the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (last searched 2009, Issue 4) for randomised controlled trials (RCTs) comparing fibrinolytic agents to treat peripheral arterial ischaemia.
SELECTION CRITERIA: RCTs comparing fibrinolytic agents to treat peripheral arterial occlusion.
DATA COLLECTION AND ANALYSIS: Data were analysed for the outcomes vessel patency, time to lysis, limb salvage, amputation, death, complications including major haemorrhage, stroke, and distal embolization.
MAIN RESULTS: Five RCTs involving a total of 687 patients with a range of clinical indications were included. In one three-pronged study, vessel patency was greater with intra-arterial recombinant tissue plasminogen activator (rt-PA) than with intra-arterial streptokinase (P < 0.04) or intravenous rt-PA (P < 0.01). In patients with peripheral arterial occlusion there was no statistically significant difference in limb salvage at 30 days with either urokinase or rt-PA, though this may reflect the small numbers in the studies. Incidences of haemorrhagic complications varied with fibrinolytic regime but there was no statistically significant difference between intra-arterial urokinase and intra-arterial rt-PA. In the three-pronged study intravenous rt-PA and intra-arterial streptokinase were associated with a significantly higher risk of haemorrhagic complications than with intra-arterial rt-PA (P < 0.05).
AUTHORS' CONCLUSIONS: There is some evidence to suggest that intra-arterial rt-PA is more effective than intra-arterial streptokinase or intravenous rt-PA in improving vessel patency in people with peripheral arterial occlusion. There was no evidence that rt-PA was more effective than urokinase for patients with peripheral arterial occlusion and some evidence that initial lysis may be more rapid with rt-PA, depending on the regime. Incidences of haemorrhagic complications were not statistically significantly greater with rt-PA than with other regimes. However, all of the findings come from small studies and a general paucity of results means that it is not possible to draw clear conclusions.
Iain Robertson; David O Kessel; David C Berridge
Related Documents :
12763493 - Arterial thromboembolism in pregnancy.
12460413 - Improvements in artery occlusion by low-density lipoprotein apheresis in a patient with...
11559503 - Migrainous spasm simulating carotid dissection: a pitfall in mr arteriographic findings.
Publication Detail:
Type:  Journal Article; Meta-Analysis; Review     Date:  2010-03-17
Journal Detail:
Title:  The Cochrane database of systematic reviews     Volume:  -     ISSN:  1469-493X     ISO Abbreviation:  Cochrane Database Syst Rev     Publication Date:  2010  
Date Detail:
Created Date:  2010-03-18     Completed Date:  2010-04-26     Revised Date:  2014-02-19    
Medline Journal Info:
Nlm Unique ID:  100909747     Medline TA:  Cochrane Database Syst Rev     Country:  England    
Other Details:
Languages:  eng     Pagination:  CD001099     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arterial Occlusive Diseases / drug therapy*
Fibrinolytic Agents / adverse effects,  therapeutic use*
Peripheral Vascular Diseases / drug therapy*
Randomized Controlled Trials as Topic
Recombinant Proteins / adverse effects,  therapeutic use
Streptokinase / adverse effects,  therapeutic use
Thrombolytic Therapy / adverse effects,  methods*
Thrombosis / drug therapy*
Tissue Plasminogen Activator / adverse effects,  therapeutic use
Urokinase-Type Plasminogen Activator / adverse effects,  therapeutic use
Grant Support
CZB/4/609//Chief Scientist Office
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Recombinant Proteins; EC 3.4.-/Streptokinase; EC Plasminogen Activator; EC Plasminogen Activator
Update In:
Cochrane Database Syst Rev. 2013;12:CD001099   [PMID:  24357258 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Tamoxifen for relapse of ovarian cancer.
Next Document:  Dornase alfa for cystic fibrosis.